J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
|
|
- Aubrie Pierce
- 6 years ago
- Views:
Transcription
1 V O L U M E 2 6 N U M B E R 1 8 J U N E JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With B-Cell Precursor Acute Lymphoblastic Leukemia and an Intrachromosomal Amplification of Chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt- Münster (ALL-BFM) Trials Andishe Attarbaschi, Georg Mann, Renate Panzer-Grümayer, Silja Röttgers, Manuel Steiner, Margit König, Eva Csinady, Michael N. Dworzak, Markus Seidel, Dasa Janousek, Anja Möricke, Carsten Reichelt, Jochen Harbott, Martin Schrappe, Helmut Gadner, and Oskar A. Haas From the Department of Pediatric Hematology and Oncology, St Anna Children s Hospital; the Children s Cancer Research Institute, Vienna, Austria; the Department of Pediatric Hematology and Oncology, Justus- Liebig-University, Giessen; and the Department of Pediatric Hematology and Oncology, Children s University Hospital, University Hospital Schleswig- Holstein, Campus Kiel, Germany. Submitted January 5, 2008; accepted March 17, Supported by the Deutsche Krebshilfe; the Österreichische Kinderkrebshilfe; the Research Program, Genome Research for Health of the Austrian Ministry of Education, Science, and Culture (Grants No. GZ /3-VI/2a/ 2002, and GZ /1-VI/1/2005); and the Fonds zur Förderung der wissenschaftlichen Forschung (FWF Grants No. P15150 and P17551B14). Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article. Corresponding author: Oskar A. Haas, MD, St Anna Children s Hospital, Kinderpitalgasse 6,Vienna, Austria, 1090; oskar.haas@stanna.at by American Society of Clinical Oncology A B S T R A C T Purpose We aimed to identify relapse predictors in children with a B-cell precursor acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iamp21), a novel genetic entity associated with poor outcome. Patients and Methods We screened 1,625 patients who were enrolled onto the Austrian and German ALL Berlin- Frankfurt-Münster (ALL-BFM) trials 86, 90, 95, and 2000 with ETV6/RUNX1-specific fluorescent in situ hybridization probes, and we identified 29 patient cases (2%) who had an iamp21. Minimal residual disease (MRD) was quantified with clone-specific immunoglobulin and T-cell receptor gene rearrangements. Results Twenty-five patients were good responders to prednisone, and all achieved remission after induction therapy. Eleven patients experienced relapse, which included eight who experienced relapse after cessation of front-line therapy. Six-year event-free and overall survival rates were 37% 14% and 66% 11%, respectively. Results of MRD analysis were available in 24 (83%) of 29 patients: nine (37.5%) belonged to the low-risk, 14 (58.5%) to the intermediate-risk, and one (4%) to the high-risk group. MRD results were available in 8 of 11 patients who experienced a relapse. Seven occurred among the 14 intermediate-risk patients, and one occurred in the high-risk patient. Conclusion The overall and early relapse rates in the BFM study were lower than that in a previous United Kingdom Medical Research Council/Childhood Leukemia Working Party study (38% v 61% and 27% v 47%, respectively), which might result from more intensive induction and early reintensification therapy in the ALL-BFM protocols. MRD values were the only reliable parameter to discriminate between a low and high risk of relapse (P.02). J Clin Oncol 26: by American Society of Clinical Oncology X/08/ /$20.00 DOI: /JCO INTRODUCTION Recently, the United Kingdom National Cancer Research Institute (NCRI) Childhood Leukemia Working Party (CLWP) reported a novel genetic entity in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) that is characterized by an intrachromosomal amplification of chromosome 21 (iamp21). 1,2 Its common defining feature is the presence of multiple copies of the RUNX1 gene that are usually contained within a morphologically abnormal chromosome 21. This gene amplification was identified by chance during fluorescent in situ hybridization (FISH) screening for ETV6/RUNX1- positive ALL; so far, FISH analysis also remains the only reliable method to identify such occurrences of ALL with an iamp21. The United Kingdom CLWP also provided the first demographic, clinical, and survival data for this specific entity. 2 The results indicated a significantly inferior survival of patients by American Society of Clinical Oncology
2 MRD-Dependent Relapse Risk of Childhood ALL With an iamp21 with an iamp21 compared with other patients with BCP-ALL. According to the highly increased relapse risk, patients with an iamp21 are now assigned into the high-risk arm of the current United Kingdom Medical Research Council (MRC)/CLWP ALL 2003 trial and, in case of a slow early response, are considered for allogeneic stem cell transplantation (SCT) in first complete remission (CR). Because this currently remains the only report of its kind, the extent that the high relapse rate of patients with an iamp21 is influenced by the composition and intensity of the applied treatment, and whether particular parameters may help to predict patients with a low and high risk of relapse, is unknown. We, therefore, report herein our experience with patients with an iamp21 who were enrolled onto the Austrian and German ALL Berlin-Frankfurt-Münster (ALL- BFM) trials. PATIENTS AND METHODS Between September 1986 and January 2007, 1,048 patients with ALL were enrolled onto four Austrian multicenter trials: ALL-BFM 86 (n 142), ALL- BFM 90 (n 256), ALL-BFM 95 (n 230), and ALL-BFM 2000 (n 420). Systematic FISH screening of 885 patient cases (84%) with ETV6/RUNX1- specific probes identified 14 patients (1.6%) with an iamp21. 3,4 An additional 15 patients with an iamp21 were identified in the German ALL-BFM studies. Eleven patient cases were detected by March 2006 (four through FISH confirmation of suggestive karyotypes and seven through retrospective FISH screening of 413 patients), and another four were detected between March 2006 and January 2007, after prospective FISH screening commenced (Table 1). All patient cases were reviewed centrally and were treated after informed consent was obtained from the patient, patient s parents, or the patient s legal guardians. 5 Follow-upwasupdatedinNovember2007.Studieswereconductedwith the approval of the responsible ethic committees. Since trial ALL-BFM 90, minimal residual disease (MRD) analysis with polymerase chain reaction based technologies for the detection of clone-specific immunoglobulin and T-cell receptor gene rearrangements was performed after completion of induction therapy (day 33) and early reintensification treatment (day 78). 6-8 However, MRD results were implemented only for risk-adapted stratification in trial ALL-BFM ETV6/RUNX1 analysis was performed with the dual color-labeled LSI ETV6/RUNX1 ES probe set (Vysis, Downers Grove, IL). An iamp21 was defined as the presence of at least five RUNX1 signals in interphase nuclei and/or the colocalization of at least three copies of the RUNX1 gene on a single chromosome 21. Hyperdiploidy was excluded with additional FISH probes in all patient cases with an iamp21. Event-free survival (EFS) and overall survival (OS) rates were analyzed according to the Kaplan-Meier method, and survival curves were compared with the log-rank test. EFS was defined as the time from diagnosis to the first adverse event or to the date of last follow-up. Inability to achieve remission (ie, early death, refractory disease), relapse at any site, death during CR, or the development of a second malignancy were considered adverse events. Patients who failed to achieve CR were assigned a failure time of zero. OS was Patient BFM Study Table 1. Clinical and Laboratory Characteristics and Outcome of the 29 Patients With ALL and an iamp21 on ALL-BFM Trials Age (years) WBC ( 10 9 /L) Phenotype Prednisone Response BM d 33 MRD Risk Relapse Time to Relapse (years) Outcome 1 A 86 F call Poor CR NA 1st CR G 86 M call Good CR NA BM 0.94 Died as a result of disease after SCT 3 A 90 F pre-b ALL Poor CR IR BM nd CR (SCT) A 90 M call Good CR IR BM nd CR (SCT) G 90 F call Good CR NA 1st CR A 95 M call Good CR IR BM 2.67 Died as a result of disease 7 A 95 F call Good CR HR BM CNS nd CR (SCT) G 95 F BCP ALL Good CR NA BM nd CR (SCT) G 95 M call Good CR NA BM 2.59 Died as a result of disease after SCT 10 A 2000 F call Good CR LR 1st CR A 2000 F call Good CR IR 1st CR A 2000 F pre-b ALL Good CR LR Died as a result of infection 1st CR 13 A 2000 M call Poor CR LR 1st CR A 2000 M call Good CR IR BM nd CR (receiving therapy) A 2000 F pre-b ALL Good CR LR 1st CR A 2000 F pre-b ALL Good CR IR 1st CR A 2000 M pre-b ALL Good CR IR 1st CR A 2000 F call Good CR IR BM 1.04 Died after SCT in 3rd CR 19 G 2000 F pre-b ALL Good CR IR 1st CR G 2000 M pre-b ALL Good CR IR 1st CR G 2000 M pre-b ALL Good CR IR BM CNS 2.28 Died as a result of disease (after SCT) 22 G 2000 M call Good CR LR 1st CR G 2000 M pre-b ALL Good CR LR 1st CR G 2000 M call Good CR LR 1st CR G 2000 M call Poor CR LR 1st CR G 2000 M call Good CR IR BM 1.62 Died as a result of disease (after SCT) 27 G 2000 F call Good CR LR 1st CR G 2000 M call Good CR IR 1st CR G 2000 F call Good CR IR 1st CR 4.47 Abbreviations: ALL, acute lymphoblastic leukemia; iamp21, intrachromosomal amplification of chromosome 21; BFM, Berlin-Frankfurt-Münster; BM, bone marrow; MRD, minimal residual disease; FU, follow-up; A, Austria; F, female; call, common acute lymphoblastic leukemia; CR, complete remission; NA, not available; M, male; G, Germany; SCT, stem-cell transplantation; IR, intermediate risk; HR, high risk; LR, low risk. FU (years) by American Society of Clinical Oncology 3047
3 Attarbaschi et al defined as the time from diagnosis to death from any cause; for surviving patients, OS was censored at the date of last follow-up. The distribution of categoric variables was analyzed by the 2 test. P values.05 were considered statistically significant. RESULTS Of the 29 patients with an iamp21, two patients were identified in trial ALL-BFM 86, three patients in trial ALL-BFM 90, four in trial ALL- BFM 95, and 20 in trial ALL-BFM 2000 (Table 1). The male-to-female ratio was 15:14, and the median age and leukocyte count at diagnosis were 9.00 years (range, 4.13 to years) and /L (range, 0.7 to /L), respectively. Twenty-five patients (86%) were good responders to prednisone and had less than 1,000/ L blasts after a 7-day prephase with prednisone and one intrathecal dose of methotrexate on day 1. All were in CR after induction therapy. Results on MRD analysis were available in 24 patients (83%). Nine patients (37.5%)wereMRD-negativeandhadtwomarkersatthelevelof10 4 after induction therapy (low risk), and 14 patients (58.5%) had levels that were less than after early reintensification therapy (intermediate risk). One patient (4%) fulfilled high-risk MRD criteria ( after early reintensification therapy). Table 2 lists clinical and laboratory characteristics and outcome data of the 29 patients with an iamp21and the 1,596 patient cases without an iamp21. Table 3 lists the data for the 29 patients on ALL-BFM trials compared with the 28 patient cases from the United Kingdom MRC/CLWP. Eleven (38%) of 29 patients experienced relapse after a median time of 2.59 years (range, 0.94 to 5.99 years): one of two patients from trial ALL-BFM 86, two of three from trial ALL-BFM 90, all four from trial ALL-BFM 95, and four of 20 patients from trial ALL-BFM MRD results were available in eight patients who experienced relapse; seven occurred among the 14 intermediate-risk patients, and one occurred in the high-risk patient. Five patients who experienced relapse have survived event-free in second CR after a median follow-up of 4.95 years (range, 0.69 to 7.18 years), which includes four who underwent SCT. Six patients who experienced a relapse died, one as a result of toxicity after SCT in third CR, four as a result of relapse after SCT in second CR, and one as a result of a second relapse after chemotherapy only. Another patient died as a result of an infection in first CR. Median follow-up of the 29 patients was 4.41 years (range, 0.24 to years), but it was less than 1 year in four patients (two each with low and intermediate MRD levels). In the 25 patients with a follow-up of more than 1 year the probabilities of 6-year EFS, relapsefree survival, and OS estimates were 38% 14%, 39% 14% and 66% 11%, respectively (Fig 1). Evaluation of potential prognostic factors (study, sex, age, leukocyte count, prednisone response, MRD levels) among the group of patients with an iamp21 revealed that MRD values were the only parameter able to predict relapsefree survival (MRD low risk [100%] v MRD intermediate risk [37% 16%]; P.02). MRD-based treatment stratification was used for the first time in ALL-BFM 2000, whereas risk assignment in ALL-BFM 86, 90, and 95 was based on conventional parameters only. 4 Conventional and MRD risk group assignment concurred in 19 (79%) of 24 patients. None of the seven patient cases in the MRD low-risk group, but five of 12 in the MRD intermediate-risk group, experienced a relapse. Of the remaining five patient cases, two patients with low MRD risk had a poor response to prednisone and were, thus, assigned to the ALL-BFM 2000 Table 2. Characteristics and Outcomes of Patients With and Without an iamp21 Characteristic Patients With an iamp21 Patients Without an iamp21 No. % No. % Total No. of patients 29 1,596 Male Female Age, years Median Range , WBC, 10 9 /L Median Range , , NA CNS disease Immunophenotype Pro-B ALL Common ALL Pre-B ALL Other T-ALL NA MRD risk group Low risk Intermediate risk High risk NA Prednisone response Good , Poor NA CR after induction therapy , Relapse Death rate year pefs year pos Abbreviations: iamp21, intrachromosomal amplification of chromosome 21; CNS, central nervous system; ALL, acute lymphoblastic leukemia; MRD, minimal residual disease; CR, complete remission; pefs, probability of event-free survival; pos, probability of overall survival. Analysis was restricted to the 877 patients with minimal residual disease data available. Including mainly patients from trials ALL-BFM 86, 90, and 95, who had not been systematically analyzed for minimal residual disease levels. Data was not disclosed because of the ongoing ALL-BFM 2000 trial; for historical comparison, the treatment results of trial ALL-BFM 95 (N 2,169) were as follows: No. of relapses: 356 (16%); 6-year probability of event-free survival: %; 6-year probability of overall survival: %. 9 Including only patients with a follow-up of more than 1 year. high-risk arm. Both are currently in first CR. The only MRD high-risk patient was treated in the ALL-BFM 95 intermediate-risk group and experienced relapse. Two other patients with MRD intermediate risk were treated according to the ALL-BFM 90 standard-risk and highrisk (poor prednisone response) arm, respectively, but both experienced relapse. However, because the ALL-BFM 90 high-risk arm was P by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
4 MRD-Dependent Relapse Risk of Childhood ALL With an iamp21 Table 3. Comparison of the Patients With ALL and an iamp21 Enrolled Onto the BFM and UK MRC/CLWP Studies Characteristic ALL-BFM Trials (86, 90, 95, 2000) UK MRC/CLWP ALL 97 Trial No. % No. % Overall No. of patients with an iamp No. of patients screened 1,625 1,630 % of patients with an iamp Male Female Age, years WBC, 10 9 /L Median CNS disease 0 0 Immunophenotype pro-b ALL 0 0 Common/pre-B ALL T-ALL 0 0 MRD risk grouping Low risk 9 31 NA Intermediate risk NA High risk 1 4 NA NA 5 17 CR after induction therapy Relapse Median time 2.59 NA During front-line therapy After cessation of therapy Death rate Median follow-up, years year pefs, % year pos, % Abbreviations: iamp21, intrachromosomal amplification of chromosome 21; MRC, Medical Research Council; CLWP, childhood leukemia working party; ALL, acute lymphoblastic leukemia; BFM, Berlin-Frankfurt-Münster; CNS, central nervous system; NA, not available; CR, complete remission; pefs, probability of event-free survival; pos, probability of overall survival. Six-year probabilities of event-free survival and of overall survival were not available for the patients from the United Kingdom study. the only one that contained neither an early reintensification nor a late reinduction element, the survival rates were inferior overall to those achieved in trials ALL-BFM 86, 95, and Of the five patients without MRD data, two were treated according to trial ALL-BFM 86 (one in the standard-risk group who experienced relapsed, and one in the high-risk group with a poor response to prednisone who did not experience relapse), one according to trial ALL-BFM 90 (intermediate risk group without relapse), and two were treated according to trial ALL-BFM 95 (one each from the standard- and intermediate-risk groups who both experienced relapse). These observations support the notion that patient cases with an iamp21 certainly benefit from risk-adapted (on the basis of prednisone response and MRD values) treatment intensifications. Event-Free and Overall Survival censored 6-year EFS: 38 ± 14% 6-year OS: 66 ± 11% Time From Diagnosis (years) Fig 1. Six-year event-free survival (EFS) and overall survival (OS) of the 25 patients with iamp21 with a follow-up of at least 1 year. DISCUSSION Compared with the outcome of the patients in the British study, patients with an iamp21 who are treated according to BFM-based regimens seem to experience a lower overall relapse rate (38% v 61%) and a lower early relapse rate (27% v 47%). In the British cohort, eight (47%) of 17 patients who experienced relapse did so during therapy, and nine (53%) experienced relapse between 8 months and 3 years off therapy.incontrast,inthebfmcohortonlythree(27%)of11patients experienced relapse early, whereas the other eight (73%) experienced relapse after cessation of front-line therapy. Moreover, one of the 28 British patients did not achieve CR at all, and three others were not in CR after induction therapy, whereas all 29 patients enrolled onto BFM trials were in CR at this time point. These differences in the overall and early disease recurrences can most likely be explained by a different effectiveness of various treatment components used in the diverse protocols. 4,10-12 For instance, 20 of 28 British patients received a three-drug (prednisone, vincristine, L-asparaginase) induction, no BFM-type early reintensification (cyclophosphamide, cytarabine, mercaptopurine), and no extracompartment therapy that would include high-dose methotrexate, whereas all three elements were consistent components of the ALL-BFM protocols. 4,10,11 Only eight of 20 British patients received a four-drug (with daunorubicine) induction and subsequent early reintensification therapy with both elements similar to the protracted and intense protocols used by the BFM Group. 4,10,11 However, because the United Kingdom CLWP study did not specify the distribution of the 17 patients who experienced relapse in the two treatment-differing trial periods, this issue cannot be additionally assessed. Nevertheless, even a dose-intensified induction treatment with an additional anthracycline in combination with an early postinduction intensification therapy is insufficient to prevent relapses in a certain proportion of patient cases with an iamp21, because the overall relapse rate was still high, even in the ALL-BFM studies. 2 The combined results of the United Kingdom MRC/CLWP and BFM trials also revealed that 16 of 28 patients who experienced relapse by American Society of Clinical Oncology 3049
5 Attarbaschi et al underwent transplantation, eight (50%) of whom are still in CR after a follow-up time between 4.91 and 7.18 years for the BFM and between 4 months and 3.67 years for the British patient cases. The comparatively good outcome of the British patients who did not undergo transplantation is difficult to interpret, because they were apparently not treated in a systematic fashion and because detailed follow-up data is not available. 2 Nevertheless, along with the continuously improved chemotherapy regimens, allogeneic SCT still remains an alternative treatment option for patient cases with an iamp21 who are in second remission. Although the distribution of patient cases with an iamp21 within the three MRD risk groups resembled that of all other BCP-ALL patient cases, it is worth noting that, except for one patient who was MRD high risk and who experienced relapse, all relapses occurred in patients with a MRD intermediate risk. The average relapse risk for all patient cases in this group is 23%, whereas it translates to 50% (7 of 14) for those with an iamp21. 6 This is, so far, one of the highest predictable relapse risks in a specific genetic childhood BCP-ALL subgroup yet identified. The results of our analysis thus demonstrate not only that MRD values reliably discriminate between patients with an iamp21 who have a low and high relapse risk but also that it is possible to extract and define a specific group of patients with clear and distinct risk features that previously remained concealed in the MRD intermediate-risk group. We conclude that, at least in the context of BFM-based treatment regimens, patient cases with an iamp21 who are MRD low risk have an excellent prognostic outlook and that, for this group, the current type of treatment is sufficient. Conversely, early treatment intensification and assignment to a high risk therapy arm is certainly warranted for those with an intermediate MRD risk. AUTHORS DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The authors indicated no potential conflicts of interest. AUTHOR CONTRIBUTIONS Conception and design: Andishe Attarbaschi, Georg Mann, Martin Schrappe, Oskar A. Haas Administrative support: Markus Seidel, Dasa Janousek Provision of study materials or patients: Renate Panzer-Grümayer, Jochen Harbott, Martin Schrappe, Oskar A. Haas Collection and assembly of data: Andishe Attarbaschi, Silja Röttgers, Manuel Steiner, Margit König, Eva Csinady, Dasa Janousek, Anja Möricke, Carsten Reichelt, Jochen Harbott Data analysis and interpretation: Andishe Attarbaschi, Georg Mann, Renate Panzer-Grümayer, Eva Csinday, Michael N. Dworzak, Anja Möricke, Jochen Harbott, Martin Schrappe, Helmut Gadner, Oskar A. Haas Manuscript writing: Andishe Attarbaschi, Michael N. Dworzak, Anja Möricke, Martin Schrappe, Helmut Gadner, Oskar A. Haas Final approval of manuscript: Andishe Attarbaschi, Georg Mann, Martin Schrappe, Helmut Gadner, Oskar A. Haas REFERENCES 1. Harewood L, Robinson H, Harris R, et al: Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: A study of 20 cases. Leukemia 17: , Moorman AV, Richards SM, Robinson HM, et al: Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iamp21). Blood 109: , Attarbaschi A, Mann G, König M, et al: Incidence and relevance of secondary chromosome abnormalities in childhood TEL/AML1 acute lymphoblastic leukemia: An interphase FISH analysis. Leukemia 18: , Schrappe M, Reiter A, Zimmermann M, et al: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995: Berlin-Frankfurt-Münster. Leukemia 14: , van der Does-van den Berg A, Bartram CR, Basso G, et al: Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the BFM Family Cooperative Group. Med Pediatr Oncol 20: , van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al: Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 352: , van der Velden VH, Cazzaniga G, Schrauder A, et al: Analysis of minimal residual disease by Ig/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data. Leukemia 21: , van der Velden VH, Panzer-Grümayer ER, Cazzaniga G, et al: Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-centre setting. Leukemia 21: , Möricke A, Reiter A, Gadner H, et al: Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood / blood [epub ahead of print on February 19, 2008] 10. Mitchell CD, Richards SM, Kinsey Se, et al: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukemia: Results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 129: , Vora A, Mitchell CD, Lennard L, et al: Toxicity and efficacy of 6-thioguanine versus mercaptopurine in childhood lymphoblastic leukemia: A randomized trial. Lancet 368: , Eden OB, Harrison C, Richards S, et al: Longterm follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, : Medical Research Council Childhood Leukemia Working Party. Leukemia 14: , 2000 Acknowledgment The Acknowledgment is included in the full-text version of this article, available online at It is not included in the PDF version (via Adobe Reader ) by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Standard risk ALL (and its exceptions
Mahshid Mehdizadeh Standard risk ALL (and its exceptions WBC at diagnosis below 50 109/L - age 1 year - no central nervous system (CNS) involvement - ETV6/RUNX1 positivity - MRD at Day
More informationSummary. Olga Zając, Katarzyna Derwich, Katarzyna Stefankiewicz, Jacek Wachowiak. Rep Pract Oncol Radiother, 2007; 12(5):
Rep Pract Oncol Radiother, 2007; 12(5): 283-288 Preliminary Communication Received: 2007.03.27 Accepted: 2007.07.24 Published: 2007.10.18 Authors Contribution: A Study Design B Data Collection C Statistical
More informationAcute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010
Acute Lymphoblastic Leukemia (ALL) Ryan Mattison, MD University of Wisconsin March 2, 2010 ALL Epidemiology 20% of new acute leukemia cases in adults 5200 new cases in 2007 Most are de novo Therapy-related
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Biondi A, Schrappe M, De Lorenzo P, et al.
More informationRisk Stratification in Childhood Leukemia
Risk Stratification in Childhood Leukemia Why is risk stratification important? Toxicities Deepa Bhojwani, MD May 11, 2018 To determine intensity of therapy - When to intensify therapy - When to de-intensify
More informationCorrelation of Sex and Remission of Acute Lymphoblastic Leukemia-L1 (ALL-L1) in Children
International Journal of Clinical and Experimental Medical Sciences 2015; 1(2): 11-15 Published online July 6, 2015 (http://www.sciencepublishinggroup.com/j/ijcems) doi: 10.11648/j.ijcems.20150102.12 Correlation
More informationFirst relapsed childhood ALL Role of chemotherapy
First relapsed childhood ALL Role of chemotherapy Thirachit Chotsampancharoen, M.D. Division of Pediatric Hematology/Oncology Department of Pediatrics Prince of Songkla University Hat-Yai, Songkhla 25
More informationElisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria
Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria Incidence Diagnosis Prognostic factors Treatment Induction therapy - HSCT Indications for HSCT
More informationJohann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD
Photo by Tynan Studio Johann Hitzler, MD, FRCPC, FAAP Jacqueline Halton, MD, FRCPC Jason D. Pole, PhD 96 Atlas of Childhood Cancer in Ontario (1985-2004) Chapter 6: Leukemia 6 Leukemia Atlas of Childhood
More informationOutcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation
Original Article Page 1 of 9 Outcome of acute leukemia patients with central nervous system (CNS) involvement treated with total body or CNS irradiation before transplantation Wen-Han Kuo 1, Yu-Hsuan Chen
More informationImproved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant
VOLUME 45 ㆍ NUMBER 2 ㆍ June 2010 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Improved outcome in childhood ALL with intensive consolidation and hematopoietic stem cell transplant Jeong A Park 1,
More informationHow Do You Measure Success in ALL?: Assessment of MRD
How Do You Measure Success in ALL?: Assessment of MD Martin Schrappe, MD, PhD University Medical Center Schleswig-Holstein Christian-Albrechts-University Kiel, Germany Topics Current risk classification
More informationMinimal residual disease: optimal methods, timing, and clinical relevance for an individual patient
DYNAMIC DISCOVERIES AND DIRECTIONS IN PEDIATRIC LEUKEMIAS Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient Martin Schrappe 1 1 Department of Pediatrics
More informationThiopurine Methyltransferase (TPMT) Genotype and Early Treatment Response to Mercaptopurine in Childhood Acute Lymphoblastic Leukemia
BRIEF REPORT Thiopurine Methyltransferase (TPMT) Genotype and Early Treatment Response to Mercaptopurine in Childhood Acute Lymphoblastic Leukemia Martin Stanulla, MD, MSc Elke Schaeffeler, PhD Thomas
More informationMANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA. BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS
MANAGEMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA BY Dr SUBHASHINI 1 st yr PG DEPARTMENT OF PEDIATRICS Introduction The management of ALL, the most common childhood malignancy (1/3 rd of all malignancy), has
More informationPrognostic significance of leukopenia in childhood acute lymphoblastic leukemia
ONCOLOGY LETTERS 7: 1169-1174, 2014 Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia YUSUKE SHIOZAWA 1, JUNKO TAKITA 1,2, MOTOHIRO KATO 3, MANABU SOTOMATSU 4, KATSUYOSHI
More informationMRD in ALL: Correct interpretation in clinical practice. Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh
MRD in ALL: Correct interpretation in clinical practice Deepak Bansal Prof., Pediatric Hematology-Oncology unit PGIMER, Chandigarh Minimal residual disease Subclinical level of residual leukemia Below
More information2011: ALL Pre-HCT. Subsequent Transplant
2011: ALL Pre-HCT The Acute Lymphoblastic Leukemia Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures ALL-specific pre-hct data such as: the recipient s hematologic and cytogenetic
More informationControversies in Hematology: Case-Based Discussion. Acute leukemia in Adolescents and Young adults October 2018, Chiang Mai Thailand
Controversies in Hematology: Case-Based Discussion Acute leukemia in Adolescents and Young adults 25-26 October 2018, Chiang Mai Thailand Associate Prof. Adisak Tantiworawit, MD Division of Hematology,
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationALL-RELAPSE GROUP Päivi Lähteenmäki on behalf of the group
ALL-RELAPSE GROUP 18.11.2014 Päivi Lähteenmäki on behalf of the group Meeting in Bergen and 2 telephone meetings (Sept, Oct) IntReALL-group in Lissabon (September, Thomas F) IntReALL SR : Denmark has registered
More informationProphylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010
Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Outline Epidemiology Risk-groups Background & Rationale
More informationAcute myeloid leukemia: prognosis and treatment. Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg
Acute myeloid leukemia: prognosis and treatment Dimitri A. Breems, MD, PhD Internist-Hematoloog Ziekenhuis Netwerk Antwerpen Campus Stuivenberg Patient Female, 39 years History: hypothyroidism Present:
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 3 JANUARY 20 2011 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Response-Guided Induction Therapy in Pediatric Acute Myeloid Leukemia With Excellent Remission Rate Jonas Abrahamsson,
More informationΙL-8 and MCP-1 in children with acute lymphoblastic leukemia and potential correlation with neurotoxicity and thromboembolic phenomena
International Journal of Diseases and Disorders ISSN: 9-985 Vol. 1 (), pp. 55-58, November, 1. Available online at www.internationalscholarsjournals.org International Scholars Journals Full Length Research
More informationAcute Lymphoblastic and Myeloid Leukemia
Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Acute Lympoblastic Leukemia Mary Eapen MD, MS Acute Lymphoblastic Leukemia SEER Age-adjusted incidence rate 1.6 per 100,000 men and women
More informationPAX5-JAK2 fusion in acute lymphoblastic leukaemia. Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne
PAX5-JAK2 fusion in acute lymphoblastic leukaemia Dr Andrew Baldi Royal Children s Hospital 24 February 2017 Melbourne Case 12-year-old girl Diagnosed with BCP ALL in November 2015 Presenting WCC 35x10
More informationPediatric Acute Leukemia: The Effect of Prognostic Factors on Clinical Outcomes at Phramongkutklao Hospital, Bangkok, Thailand
Pediatric Acute Leukemia: The Effect of Prognostic Factors on Clinical Outcomes at Phramongkutklao Hospital, Bangkok, Thailand Piya Rujkijyanont MD*, Suphathida Kaewinsang MD*, Chalinee Monsereenusorn
More informationRole of FISH in Hematological Cancers
Role of FISH in Hematological Cancers Thomas S.K. Wan PhD,FRCPath,FFSc(RCPA) Honorary Professor, Department of Pathology & Clinical Biochemistry, Queen Mary Hospital, University of Hong Kong. e-mail: wantsk@hku.hk
More informationOriginal article. Key words: Lymphoblastic leukemia, Acute, Childhood, Minimal residual disease, Flow cytometry
Original article DOI: 10.5/kjp.2010.5.11.957 Korean J Pediatr 2010;5(11):957-96 Prognostic significance of minimal residual disease detected by a simplified flow cytometric assay during remission induction
More informationThe probability of curing children with acute. brief report
brief report Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) Khadra
More informationPediatric Acute Lymphoblastic Leukemia. Highlights of ASH 2015
Pediatric Acute Lymphoblastic Leukemia Highlights of ASH 2015 Thai National Protocol Outcomes Outcome is very dependent on treatment Patient s compliance Treatment of ALL Induction Intensification Maintenance
More information7th International Symposium on Acute Promyelocytic Leukemia, Rome, September 24 27, Eva Lengfelder
Frontline therapy of acute promyelocytic leukemia: randomized comparison of ATRA and intensified chemotherapy including high dose cytosine-arabinoside versus ATRA and anthracyclines - A prospective multicenter
More informationImproving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease
Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients with Earlier Quantification of Minimal Residual Disease Mawar Karsa 1, Luciano Dalla Pozza 2, Nicola C. Venn
More informationPublished Ahead of Print on January 12, 2017, as doi: /haematol Copyright 2017 Ferrata Storti Foundation.
Published Ahead of Print on January 12, 2017, as doi:10.3324/haematol.2016.153957. Copyright 2017 Ferrata Storti Foundation. Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment
More informationAbstract 861. Stein AS, Topp MS, Kantarjian H, Gökbuget N, Bargou R, Litzow M, Rambaldi A, Ribera J-M, Zhang A, Zimmerman Z, Forman SJ
Treatment with Anti-CD19 BiTE Blinatumomab in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL) Post-Allogeneic Hematopoietic Stem Cell Transplantation Abstract
More informationAdult ALL: NILG experience
Adult ALL: NILG experience R Bassan USC Ematologia, Ospedali Riuniti, Bergamo SIE Interregionale, Padova 12 5 2011 Now and then Northern Italy Leukemia Group 2000-10 Prospective clinical trials 09/00 10/07
More informationCurrent Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review
EXPERT OPINION Current Indications of Bone Marrow Transplantation (BMT) in Pediatric Malignant Conditions; a Review Chi-Kong Li Department of Pediatrics, Prince of Wales Hospital, The Chinese University
More informationTCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations.
Supplementary Figure 1 TCF3 breakpoints of TCF3-PBX1 (patients 1a 5a) and TCF3-HLF (patients 6a 9a and11a) translocations. The CpG motifs closest to the breakpoints are highlighted in red boxes and the
More informationClinical characteristics and prognosis of pediatric patients with B cell acute lymphoblastic leukemia relapse
ONCOLOGY LETTERS 16: 2929-2934, 2018 Clinical characteristics and prognosis of pediatric patients with B cell acute lymphoblastic leukemia relapse XIAOHONG ZHANG 1*, HAIXIA WU 2*, HONG FAN 3, BAIFANG SU
More informationJPMA ( Journal Of Pakistan Medical Association) Vol 53, No.9,Sep Original Articles
JPMA ( Journal Of Pakistan Medical Association) Vol 53, No.9,Sep. 2003 Original Articles Outcome of Adult Acute Lymphoblastic Leukemia: a Single Center Experience M. Usman, I. Burney*, A. Nasim*, S. N.
More informationCase Report Extra Copies of der(21)t(12;21) plus Deletion of ETV6 Gene due to dic(12;18) in B-Cell Precursor ALL with Poor Outcome
Case Reports in Genetics Volume 2012, Article ID 186532, 4 pages doi:10.1155/2012/186532 Case Report Extra Copies of der(21)t(12;21) plus Deletion of ETV6 Gene due to dic(12;18) in B-Cell Precursor ALL
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 19 Dec 2018 02:45:15 GMT) CTRI Number Last Modified On 25/12/2017 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationSUPPLEMENTARY FIG. S3. Kaplan Meier survival analysis followed with log-rank test of de novo acute myeloid leukemia patients selected by age <60, IA
Supplementary Data Supplementary Appendix A: Treatment Protocols Treatment protocols of 123 cases patients were treated with the protocols as follows: 110 patients received standard DA (daunorubicin 45
More informationMS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD
MS.4/ 27.02.2019 Acute Leukemia: AML Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationMS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi
MS.4/ 1.Nov/2015. Acute Leukemia: AML Abdallah Abbadi Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk
More informationMUD SCT for Paediatric AML?
7 th South African Symposium on Haematopoietic Stem Cell Transplantation MUD SCT for Paediatric AML? Alan Davidson Haematology / Oncology Service Red Cross Children s Hospital THE SCENARIO A 10 year old
More informationRelapsed acute lymphoblastic leukemia. Lymphoma Tumor Board. July 21, 2017
Relapsed acute lymphoblastic leukemia Lymphoma Tumor Board July 21, 2017 Diagnosis - Adult Acute Lymphoblastic Leukemia (ALL) Symptoms/signs include: Fever Increased risk of infection (especially bacterial
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationCase 1. Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX
Case 1 Sa A.Wang, MD UT MD Anderson Cancer Center Houston, TX Disclosure of Relevant Financial Relationships The USCAP requires that anyone in a position to influence or control the content of all CME
More informationETP - Acute Lymphoblastic Leukaemia
ETP - Acute Lymphoblastic Leukaemia Dr Sally Campbell - Royal Children s Hospital Melbourne 24 February 2017 T-ALL 12-15% of all newly diagnosed ALL cases in pediatrics are T-ALL T-ALL behaves differently
More informationMyeloma Support Group: Now and the Horizon. Brian McClune, DO
Myeloma Support Group: Now and the Horizon Brian McClune, DO Disclosures Consultant to Celgene Objectives Transplant for myeloma- is there any thing new? High risk disease University protocols New therapies?
More informationSUPPLEMENTARY FILE GRAALL and GRAALL PROTOCOLS
SUPPLEMENTARY FILE GRAALL- 2003 and GRAALL- 2005 PROTOCOLS INTRODUCTION 1 FIGURE 1. GRAALL- 2003 AND GRAALL- 2005 OVERALL SURVIVAL 2 GRAALL- 2003 PROTOCOL 3 1. GENERAL STUDY DESIGN 3 2. INCLUSION AND NON-
More informationETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol
Wang et al. Italian Journal of Pediatrics (2018) 44:94 https://doi.org/10.1186/s13052-018-0541-6 RESEARCH Open Access ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis
More informationAcute leukemia & agressive lymphoma in children
Acute leukemia & agressive lymphoma in children Barbara De Moerloose Dept. Pediatric Hematology-Oncology and Stem Cell Transplantation Ghent University Hospital barbara.demoerloose@uzgent.be * Childhood
More informationCorporate Medical Policy. Policy Effective February 23, 2018
Corporate Medical Policy Genetic Testing for FLT3, NPM1 and CEBPA Mutations in Acute File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_flt3_npm1_and_cebpa_mutations_in_acute_myeloid_leukemia
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationEarly Clearance of Peripheral Blood Blasts Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia
Early Clearance of Peripheral Blood Blasts Predicts Response to Induction Chemotherapy in Acute Myeloid Leukemia Martha Arellano, MD 1 ; Suchita Pakkala, MD 1 ; Amelia Langston, MD 1 ; Mourad Tighiouart,
More informationIntroduction LYMPHOID NEOPLASIA
LYMPHOID NEOPLASIA Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies Nicola Gökbuget,
More informationAcute Myeloid and Lymphoid Leukemias
Acute Myeloid and Lymphoid Leukemias Hugo F. Fernandez, MD Department of Malignant Hematology & Cellular Therapy Moffitt at Memorial Healthcare System April 29, 2018 15 th Annual Miami Cancer Meeting Objectives
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationMinimal residual disease (MRD) in AML; coming of age. Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital
Minimal residual disease (MRD) in AML; coming of age Dr. Mehmet Yılmaz Gaziantep University Medical School Sahinbey Education and Research hospital 1. The logistics of MRD assessment in AML 2. The clinical
More informationCase Report T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission
Case Reports in Hematology, Article ID 359158, 4 pages http://dx.doi.org/10.1155/2014/359158 Case Report T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission Lauren Elreda, 1
More informationCLINICAL SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
CLINICAL SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA CLINICAL SIGNIFICANCE OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA HÉLÈNE CAVÉ, PH.D.,
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment
More informationHandout for lecture on lymphoblastic neoplasms presented by Rob McKenna
Handout for lecture on lymphoblastic neoplasms presented by Rob McKenna The following slides represent a near final version of the presentation that will be given in Maui, January 23,2018. Minor changes
More informationPhiladelphia chromosome-positive acute lymphoblastic leukemia in childhood
Review article DOI: 10.3345/kjp.2011.54.3.106 Korean J Pediatr 2011;54(3):106-110 Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood Hong Hoe Koo, M.D., Ph.D. Department of Pediatrics,
More informationPhiladelphia-positive Acute Lymphoblastic Leukemia
Philadelphia-positive Acute Lymphoblastic Leukemia Nicolas Boissel Service d Hématologie Unité Adolescents et Jeunes Adultes Hôpital Saint-Louis, Paris Ph+ acute lymphoblastic leukemia DR+, CD19+, CD22+,
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationP53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse
Blood First Edition Paper, prepublished online August 31, 2004; DOI 10.1182/blood-2004-04-1363 P53 Gene Deletion Detected By Fluorescence In Situ Hybridization is an Adverse Prognostic Factor for Patients
More informationKYMRIAH (tisagenlecleucel)
KYMRIAH (tisagenlecleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and
More informationRisk-adapted stratification and treatment of childhood ALL
Risk-adapted stratification and treatment of childhood ALL Martin Schrappe ALL-BFM Study Group International BFM Study Group Department of Pediatrics University Medical Center Schleswig-Holstein Kiel Germany
More informationMolecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note
Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note MPEP/MPC Advice Note 2016-02 June 2016 Test evaluated: Tumour Protein p53 (TP53) Molecular Pathology Evaluation Panel
More informationRemission induction in acute myeloid leukemia
Int J Hematol (2012) 96:164 170 DOI 10.1007/s12185-012-1121-y PROGRESS IN HEMATOLOGY How to improve the outcome of adult acute myeloid leukemia? Remission induction in acute myeloid leukemia Eytan M. Stein
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationN Engl J Med Volume 373(12): September 17, 2015
Review Article Acute Myeloid Leukemia Hartmut Döhner, M.D., Daniel J. Weisdorf, M.D., and Clara D. Bloomfield, M.D. N Engl J Med Volume 373(12):1136-1152 September 17, 2015 Acute Myeloid Leukemia Most
More informationNIH Public Access Author Manuscript Pediatr Blood Cancer. Author manuscript; available in PMC 2010 March 1.
NIH Public Access Author Manuscript Published in final edited form as: Pediatr Blood Cancer. 2009 March ; 52(3): 335 339. doi:10.1002/pbc.21817. Intensive Chemotherapy for Systemic Anaplastic Large Cell
More informationImpact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete Response in Acute Myeloid Leukemia Cases
DOI:10.22034/APJCP.2018.19.2.421 RESEARCH ARTICLE Editorial Process: Submission:08/01/2017 Acceptance:12/09/2017 Impact of Day 14 Bone Marrow Biopsy on Re-Induction Decisions and Prediction of a Complete
More informationPETHEMA; 2 HOVON; 3 PLAG and 4 GATLA Groups.
Clinical significance of complex karyotype at diagnosis in Pa7ents with Acute Promyelocy7c Leukemia Treated with ATRA and chemotherapy based PETHEMA trials Labrador J 1, Montesinos P 1, Bernal T 1, Vellenga
More informationPacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018
Pacharapan Surapolchai, MD Associate Professor Department of Pediatrics, Faculty of Medicine, Thammasat University, Thailand October 2018 Outline Case study Introduction of Current management of infantile
More informationNew drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna
New drugs in Acute Leukemia Cristina Papayannidis, MD, PhD University of Bologna Challenges to targeted therapy in AML Multiple subtypes based upon mutations/cytogenetic aberrations No known uniform genomic
More informationCAALL-F01 OVERVIEW, OUTLINES COMITE LEUCEMIES 19 NOVEMBRE 2015
CAALL-F01 OVERVIEW, OUTLINES COMITE LEUCEMIES 19 NOVEMBRE 2015 Current outcomes in childhood and adolescent ALL: FRALLE 2000 protocol: 2176 pts; 1-20 years FRALLE Group Event-Free Overall Survival Survival
More informationBackground. Outcomes in refractory large B-cell lymphoma with traditional standard of care are extremely poor 1
2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma Abstract 2967 Neelapu SS, Ghobadi A, Jacobson
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationMEETING SUMMARY ASH 2018, San Diego, USA
MEETING SUMMARY ASH 2018, San Diego, USA Prof. Stefano Luminari University of Modena and Reggio Emilia, Italy AN UPDATE ON PROGNOSTIC FACTORS IN INDOLENT LYMPHOMAS 2 DISCLAIMER Please note: The views expressed
More informationSummary. Table 1 Blinatumomab administration, as per European marketing authorisation
Cost-effectiveness of blinatumomab (Blincyto ) for the treatment of relapsed or refractory B precursor Philadelphia chromosome negative acute lymphoblastic leukaemia in adults. The NCPE assessment of blinatumomab
More informationHematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
Hematology Measure #1: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow This measure may be used as an Accountability measure Clinical Performance
More informationJordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party. The European Group for Blood and Marrow Transplantation
36th EBMT & 9th Data Management Group Annual Meeting Vienna, 23 March 2010 Jordi Esteve Hospital Clínic (Barcelona) Acute Leukemia Working Party The European Group for Blood and Marrow Transplantation
More informationPediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08)
Pediatric Acute Lymphoblastic Leukemia Protocol 2008 (PALL08) Department of Pediatric Hematology/Oncology King Fahd National Centre for Children s Cancer and Research King Faisal Specialist Hospital and
More informationLeukemia. Andre C. Schuh. Princess Margaret Cancer Centre Toronto
Leukemia Andre C. Schuh Princess Margaret Cancer Centre Toronto AGENDA Ø Overview Ø Key News This Year Ø Key News out of ASH 2016 Sessions Abstracts Ø Canadian Perspective Ø Overview 2015- Stone, R. et
More information